Asklepios BioPharmaceutical
↗Research Triangle Park, North Carolina, USA
Asklepios BioPharmaceutical (AskBio) is a fully integrated gene therapy company specializing in the development and manufacturing of adeno-associated virus (AAV) gene therapeutics. Founded in 2001, the company pioneered rAAV technology and operates across multiple therapeutic areas including neuromuscular, central nervous system (CNS), cardiovascular, and metabolic diseases. AskBio is now a wholly owned and independently operated subsidiary of Bayer AG, acquired in 2020. The company maintains a comprehensive clinical pipeline targeting rare genetic disorders and complex diseases with unmet medical needs. In addition to drug development, AskBio operates Viralgen, a state-of-the-art CDMO (Contract Development and Manufacturing Organization) subsidiary specializing in cGMP AAV manufacturing with facilities in Spain, and BrainVectis, focused on CNS-targeted gene therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:2001
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Private Subsidiary
Total Raised:$235M
Investors:TPG Capital, Vida Ventures, AustralianSuper, Columbus Venture Partners, Springboard Enterprises
PIPELINE
Stage:Phase 1|Phase 2|Preclinical
Lead Drug Stage:Phase 2
Modalities:AAV Gene Therapy, rAAV vectors, AAV2, Gene Editing
Active Trials:6
Trial Phases:Phase 1: 2 | Phase 2: 4
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Bayer AG
Acquired By:Bayer AG (2020-11-01)
Subsidiaries:Viralgen Vector Core (CDMO operations in Spain), BrainVectis (CNS-focused gene therapy)
Key Partnerships:Selecta Biosciences: Strategic partnership for AAV gene therapy development; licensed ImmTOR immune tolerance platform for Pompe disease, ReCode Therapeutics: Strategic collaboration to explore single vector gene editing platform, Hansa Biopharma: Feasibility evaluation of imlifidase as pre-treatment for AAV gene therapy in Pompe disease, Bayer AG: Parent company providing strategic oversight, manufacturing support, and clinical development resources
COMPETITION
Position:Leader
Competitors:Spark Therapeutics, uniQure, Bluebird Bio, Abeona Therapeutics, Freeline Therapeutics, Novartis (AveXis), Biogen, Gilead Sciences +1 more
LEADERSHIP
Key Executives:
Gustavo Pesquin - Chief Executive Officer
Josh Grieger - Chief Technology Officer
Canwen Jiang - Chief Development Officer and Chief Medical Officer
Tracy Dowling - Chief Business Officer and General Counsel
Mansuo Shannon - Chief Scientific Officer
Scientific Founders:R. Jude Samulski, Ph.D., Sheila Mikhail
Board Members:R. Jude Samulski (Co-Founder, Board Member), Sheila Mikhail (Co-Founder, Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Asklepios BioPharmaceutical. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.